OMALIZUMAB IS RECOMMENDED FOR THE TREATMENT OF CHRONIC IDIOPATHIC URTICA RESISTANT TO H1-HISTAMINE RECEPTOR BLOCKERS IN PATIENTS 12 YEARS OF AGE AND OLDER.

Omalizumab is indeed recommended for the treatment of chronic idiopathic urticaria that is resistant to H1-histamine receptor blockers in patients who are 12 years of age and older. This recommendation is based on clinical trials that have shown the effectiveness of Omalizumab in reducing the symptoms of chronic idiopathic urticaria.

Here are the steps for this treatment:

1. Diagnosis: The first step is to diagnose the condition. Chronic idiopathic urticaria is characterized by the presence of hives, itching, and/or angioedema for six weeks or longer, with no apparent cause.

2. Initial Treatment: The initial treatment for chronic idiopathic urticaria typically involves the use of H1-histamine receptor blockers. These medications work by blocking the action of histamine, a substance in the body that causes allergic symptoms.

3. Assessing Resistance: If the symptoms of chronic idiopathic urticaria persist despite the use of H1-histamine receptor blockers, the condition is considered to be resistant to these medications.

4. Omalizumab Treatment: In cases where the condition is resistant to H1-histamine receptor blockers, the use of Omalizumab is recommended. Omalizumab is an injectable medication that works by reducing the immune system's response to allergens.

5. Monitoring: After starting Omalizumab, it's important to monitor the patient's response to the medication and adjust the treatment plan as necessary.

Remember, this is a general guide and individual treatment plans may vary based on the patient's specific needs and medical history. Always consult with a healthcare provider for personalized medical advice.